Immune checkpoint inhibitors (ICI), monoclonal antibodies targeting immune checkpoints, such as programmed death-1 (PD-1), its ligand (PD-L1) (3), or cytotoxic T lymphocyte antigen-4 (CTLA-4), disrupt immune tolerance by blocking regulators of T cell activation and allowing effective anti-tumor response (4). Here, CTLA4 is linked to neoplasm.